

Cases from the Community: Urologic Oncology Investigators Provide Perspectives on the Optimal Management of Prostate Cancer (Webinar Video Proceedings)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Ongoing Phase III trials are evaluating talazoparib in combination with which of the following agents for prostate cancer?**
 - Enzalutamide
 - ¹⁷⁷Lu-PSMA-617
 - Darolutamide
 - All of the above
- The addition of which of the following to docetaxel and ADT for metastatic hormone-sensitive prostate cancer resulted in a statistically significant improvement in overall survival in the Phase III ARASENS study?**
 - Apalutamide
 - Enzalutamide
 - Darolutamide
 - Relugolix
- The results of the Phase III PROpel trial of first-line olaparib in combination with abiraterone versus abiraterone alone reported an improvement in radiographic progression-free survival for patients with metastatic castration-resistant prostate cancer (mCRPC) and what homologous recombination repair (HRR) gene mutation status?**
 - HRR gene mutations
 - No HRR gene mutations
 - All patients regardless of HRR gene mutation status
 - No patients regardless of HRR gene mutation status
- Which of the following any-grade adverse events was most commonly observed in patients with mCRPC receiving ¹⁷⁷Lu-PSMA-617 in the VISION study?**
 - Bruising
 - Thrombocytopenia
 - Leukopenia
 - Dry mouth
- Which agent resulted in a lower cumulative incidence of major cardiovascular adverse events for patients with advanced prostate cancer in the HERO trial?**
 - Relugolix
 - Leuprolide
 - Degarelix
 - Sipuleucel-T